Search Results for 'roche'
Contract Service Directory Companies
View All Buyers Guide Companies »
-
Financial Reports
Financial Report: Roche 1H Results
Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing.07.22.21
-
Trials & Filings
Japan First to Approve Roche’s Ronapreve to Treat COVID-19
Full approval is based on a global phase III trial which found casirivimab and imdevimab reduced hospitalization or death by 70%.07.21.21
-
-
Mimetas, Roche to Develop Human Disease Models for Drug Development
Will focus on tailor-made phenotypic models for IBD and HBV.07.06.21
-
Breaking News | Trials & Filings
Roche’s Actemra Receives FDA EUA to Treat COVID-19
Authorization enables emergency use of Actemra in hospitalized adult and pediatric patients.06.28.21
-
Financial Reports
Financial Report: Roche
Newly launched medicines Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla offset the impact of competition from biosimilars for established medicines.Kristin Brooks 02.05.21
-
Breaking News | Clinical Trials | Drug Development | Industry News
Affimed, Roche Explore AFM24, Tecentriq Combo
To investigate the combination for the treatment of advanced solid epidermal growth factor receptor (EGFR) expressing malignancies.Kristin Brooks 02.03.21
-
Breaking News | Collaborations & Alliances | Industry News
Lead Pharma and Roche Enter Collaboration & License Agreement
Will develop oral small molecules to treat immune mediated diseases.Contract Pharma Staff 11.16.20
-
Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
CEVEC, Roche Ink ELEVECTA Technology License Agreement
Allows Roche to use CEVEC's ELEVECT Technology for AAV vector manufacturing for its portfolio of gene therapy products.Contract Pharma Staff 11.11.20
-
Breaking News | cGMP Manufacture | Drug Development | Industry News
Roche, Atea Pharma to Develop Potential Oral COVID-19 Treatment
To develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral being studied to treat COVID-19.Contract Pharma Staff 10.22.20
-
Bio News | Breaking News | Facilities | Industry News
Roche Canada to Invest $500M to Create 500 Jobs in Ontario
City of Mississauga applauds Roche Canada jobs investment in Life Sciences Industry.Contract Pharma Staff 10.21.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
Dyno, Roche Ink Gene Therapy Deal Worth up to $1.8B
Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ gene therapy capabilities.Contract Pharma Staff 10.14.20
-
Breaking News | Industry News
PTC Therapeutics Achieves $20M Roche Milestone
Payment was triggered by the first commercial sale of Evrysdi in the U.S. which was approved by the FDA on August 7 to treat SMA.Contract Pharma Staff 08.27.20
-
cGMP Manufacture | Collaborations & Alliances | Drug Development | Scale-up/Technology Transfer
Roche, Regeneron Partner to Increase Global Supply of REGN-COV2
To develop, manufacture and distribute REGN-COV2, Regeneron’s investigational antiviral antibody combination to treat COVID-19.Contract Pharma Staff 08.19.20
-
Breaking News | Trials & Filings
Roche's Rozlytrek Wins EU Approval
For the treatment of solid tumors expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion and ROS1-positive, advanced non-small cell lung cancer.Contract Pharma Staff 08.03.20
-
Breaking News | Trials & Filings
FDA Approves Roche’s Tecentriq Combo for Melanoma
Tecentriq with Cotellic and Zelboraf helped people live longer without disease worsening or death compared to placebo.Contract Pharma Staff 07.31.20
-
Breaking News | Clinical Trials | Industry News
Roche’s Phase III Trial of Actemra in COVID-19 Misses Primary Endpoint
COVACTA trial did not meet primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoints.Contract Pharma Staff 07.30.20
-
-
Breaking News | Clinical Trials | Drug Development | Trials & Filings
Roche Initiates Phase III Trial in COVID-19 Pneumonia
To evaluate Actemra/RoActemra plus remdesivir in hospitalized patients with severe Pneumonia.Contract Pharma Staff 05.28.20
-
Bio News | Drug Development | Drug Discovery | Industry News
Roche Becomes Founding Partner in BaseLaunch
Basel Area-based incubator that helps entrepreneurs launch biotech companies begins next phase of its company building activities.Contract Pharma Staff 05.15.20
-
Breaking News | Financial Reports
Financial Report: Roche
Pharmaceutical sales up 3% in the quarter, driven by Tecentriq, Hemlibra, Ocrevus and Perjeta.Contract Pharma Staff 04.22.20
-
Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
Arrakis, Roche Ink Multi-Billion Dollar Deal to Develop RNA-based Therapies
Multi-target program to utilize RNA-targeted small molecule drug discovery platformContract Pharma Staff 04.09.20
-
Breaking News | Drug Development | Industry News
Roche Accelerates Phase III Actemra Trial in COVID-19
Receives $25 million in support from BARDA to evaluate safety and efficacy in severe COVID-19 pneumoniaContract Pharma Staff 04.08.20
-
Breaking News | Industry News
FDA’s CTAP to Expedite COVID-19 Countermeasures
New program across public, academic and private sectors aims to expedite the development of life-saving treatmentsContract Pharma Staff 04.07.20
-
Breaking News | Industry News | Promotions & Moves
Wacker Biosolutions Under New Leadership
Dr. Susanne Leonhartsberger takes the helm as president04.01.20
-
Breaking News | Promotions & Moves
Samsung Biologics Appoints BD VP for CDO Biz
Ms. Yang brings 20 years of experience in marketing, sales, and business development at global pharmaceutical companies.03.31.20
-
Breaking News | Collaborations & Alliances | Drug Development
Forge, Roche Enter Antibiotic Alliance
To develop novel antibiotic to treat serious lung infections attributed to antibiotic-resistant Gram-negative bacteria03.25.20
-
Breaking News | Clinical Trials | Drug Development | Industry News | Trials & Filings
Roche Trial to Assess Actemra/RoActemra in COVID-19 Pneumonia
First Phase III global study of Actemra/RoActemra in this setting to evaluate the safety and efficacy in collaboration with BARDA03.19.20
-
Breaking News | Industry News
Roche Ships First 400,000 COVID-19 Tests
Labs across U.S. to begin patient testing under FDA Emergency Use Authorization03.17.20
-
Breaking News | Industry News
Roche’s SARS-CoV-2 Test Receives EUA
First commercial test for SARS-CoV-2 will enable expedited coronavirus testing with results in three and half hours03.13.20
-
APIs
Drug Substance Cost: A Non-Issue?
Insight and implications of drug substance cost analysis.Dr. Michele Jermini and Dr. Enrico Polastro 03.04.20
-
Biologics, Proteins, Vaccines | Breaking News | CRO News | Industry News | Promotions & Moves | R&D
Aragen Appoints Steven Lang as VP Biologics
The addition of Dr. Lang is part of a multiyear investment in Aragen’s team, facilities and technologies02.28.20
-
Breaking News | Chemistry | Drug Development | Industry News | Information Technology
Pistoia Alliance’s UDM Project Reaches Milestone
Latest UDM helps build comprehensive data model for chemical reactions to support Lab of The Future and AI adoption02.25.20
-
Breaking News | Collaborations & Alliances | Drug Development | Industry News
Nimble Collaborates with Genentech
Collaboration will discover and develop novel peptide-based therapeutics02.20.20
-
Breaking News | Financial Reports
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Industry News
ProBioGen Inks Commercial GlymaxX License with Roche
ADCC-enhancement for innovative cancer therapy.01.13.20
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Roche Licenses ProBioGen’s GlymaxX Technology
ADCC-enhancement will be applied to innovative cancer therapy01.08.20
-
Drug Development | R&D
Top Pharma M&A Deals of 2019
Drug manufacturers spent a record $342 billion on Mergers & AcquisitionsOnline Exclusives Kristin Brooks, Contract Pharma 12.23.19
-
Breaking News | Industry News
Roche Completes Spark Acquisition
Will continue to operate as an independent company within the Roche Group12.17.19
-
Promotions & Moves
Nektar Therapeutics Appoints SVP and CCO
John Northcott brings extensive commercial experience, including pre-launch planning and on-market commercialization in oncology12.03.19
-
Breaking News | Collaborations & Alliances | Drug Development | Trials & Filings
Roche’s Risdiplam for SMA Granted Priority Review
FDA filing triggers $15M milestone to development partner PTC Therapeutics11.25.19
-
Drug Development | Industry News
Roche to Acquire Promedior in $1.4B Transaction
Gains full rights to Promedior's entire portfolio of molecules for serious fibrotic diseases11.15.19
-
Breaking News | Collaborations & Alliances | Drug Development
Genentech Selects Affimed Target in Immunotherapy Alliance
Genentech is responsible for clinical development and commercialization worldwide11.08.19
-
Beyond the Pills - A Blueprint for Designing Complex Small Molecule Formulations of the Future
...10.28.19
-
APIs | Cytotoxics and High Potency Manufacturing | Facilities
Flamma Arrives in the U.S.
Italian CDMO sets down roots in the U.S. market with purchase of Teva facility.Tim Wright, Editor, Contract Pharma 10.15.19
-
Promotions & Moves
Avidity Biosciences Appoints President and CEO
Sarah Boyce brings extensive experience in the life sciences industry10.01.19
-
Cytotoxics and High Potency Manufacturing
-
Roche’s Tecentriq/Abraxane Combo for TNBC Approved by EU
The Tecentriq combination marks the first cancer immunotherapy regimen to be available in Europe for triple-negative breast cancer08.29.19
-
Breaking News | Collaborations & Alliances | Drug Delivery | Industry News
Enable Injections, Genentech Form Partnership
enFuse technology allows patients to self-administer subcutaneous treatments outside of clinical setting08.21.19
-
Drug Development | Trials & Filings
Roche Wins Two Approvals for Cancer Drug Rozlytrek
Becomes third tumor-agnostic drug to win FDA Approval08.16.19
